When asked about the interim data, Nader seemed emphatic IMO, that only one person, someone at Amerix, "has seen" the interim data. Later, and twice actually, he said the FDA firewall statitician "has" the interim data, but he did not state this with any emotion, as if it was not a big deal. My thoughts now are that the FDA firewall statistician does "have the interim data", but this is somehow standard, and this person does not work for the FDA, nor has this person actually "seen" the data, nor can this person use the interim data in any way to influence the FDA to grant to any doctors or hospitals, access to Leronlimab. Another option as stated recently on IH, is, that we don't know what all this means. I would hope it could mean the FDA wants to look and possibly grant some type of access to Leronlimab.